Chengdu Sheng Nuo Biotec (688117.SH): Vipadenant API Receives Marketing Approval

Stock News11-19

Chengdu Sheng Nuo Biotec Co., Ltd. (688117.SH) announced that its wholly-owned subsidiary, Chengdu Sheng Nuo Biopharmaceutical Co., Ltd., recently received the "Chemical Drug Substance Marketing Approval Notice" for Vipadenant active pharmaceutical ingredient (API) from the National Medical Products Administration (NMPA).

Vipadenant is a polyethylene glycol (PEG)-modified exenatide that binds to and activates GLP-1 receptors as a GLP-1 receptor agonist. It shares similar physiological effects with natural human GLP-1, lowering blood glucose levels in a glucose-dependent manner by enhancing insulin secretion. The drug is indicated for treating type 2 diabetes and obesity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181325830?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 16:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181325830","market":"hk","top_or_hot":-1,"title":"Chengdu Sheng Nuo Biotec (688117.SH): Vipadenant API Receives Marketing Approval","media":"Stock News","content":"<p>Chengdu Sheng Nuo Biotec Co., Ltd. (688117.SH) announced that its wholly-owned subsidiary, Chengdu Sheng Nuo Biopharmaceutical Co., Ltd., recently received the \"Chemical Drug Substance Marketing Approval Notice\" for Vipadenant active pharmaceutical ingredient (API) from the National Medical Products Administration (NMPA).</p>\n<p>Vipadenant is a polyethylene glycol (PEG)-modified exenatide that binds to and activates GLP-1 receptors as a GLP-1 receptor agonist. It shares similar physiological effects with natural human GLP-1, lowering blood glucose levels in a glucose-dependent manner by enhancing insulin secretion. The drug is indicated for treating type 2 diabetes and obesity.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chengdu Sheng Nuo Biotec (688117.SH): Vipadenant API Receives Marketing Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChengdu Sheng Nuo Biotec (688117.SH): Vipadenant API Receives Marketing Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-19 16:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chengdu Sheng Nuo Biotec Co., Ltd. (688117.SH) announced that its wholly-owned subsidiary, Chengdu Sheng Nuo Biopharmaceutical Co., Ltd., recently received the \"Chemical Drug Substance Marketing Approval Notice\" for Vipadenant active pharmaceutical ingredient (API) from the National Medical Products Administration (NMPA).</p>\n<p>Vipadenant is a polyethylene glycol (PEG)-modified exenatide that binds to and activates GLP-1 receptors as a GLP-1 receptor agonist. It shares similar physiological effects with natural human GLP-1, lowering blood glucose levels in a glucose-dependent manner by enhancing insulin secretion. The drug is indicated for treating type 2 diabetes and obesity.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688117","symbol_name":"圣诺生物","start_time":0,"source_url":"","article_id":"1181325830","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181325830","pubTimestamp":1763539572,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Chengdu Sheng Nuo Biotec Co., Ltd. (688117.SH) announced that its wholly-owned subsidiary, Chengdu Sheng Nuo Biopharmaceutical Co., Ltd., recently received the \"Chemical Drug Substance Marketing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688117":"圣诺生物","BK0239":"医药制造"},"translate_title":"成都圣诺生物（688117.SH）：维帕地南原料药获上市批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688117":1},"content_text":"Chengdu Sheng Nuo Biotec Co., Ltd. (688117.SH) announced that its wholly-owned subsidiary, Chengdu Sheng Nuo Biopharmaceutical Co., Ltd., recently received the \"Chemical Drug Substance Marketing Approval Notice\" for Vipadenant active pharmaceutical ingredient (API) from the National Medical Products Administration (NMPA).\nVipadenant is a polyethylene glycol (PEG)-modified exenatide that binds to and activates GLP-1 receptors as a GLP-1 receptor agonist. It shares similar physiological effects with natural human GLP-1, lowering blood glucose levels in a glucose-dependent manner by enhancing insulin secretion. The drug is indicated for treating type 2 diabetes and obesity.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181325830","isCrawlerRequest":true}